Portage Biotech Inc. and its subsidiaries conduct research and development for pharmaceutical and biotechnology products, which includes various iNKT cell activators and other vaccines. The company also creates nanolipogel technology for use in immune-oncology, and antibodies for monotherapy and combination therapy to treat solid and haematological malignancies. Additionally, they develop antibodies related to the inflammatory tumor and tumor-infiltrating immune cell microenvironments, FOXO4-P53 modulator, and C-RAF inhibitor.